Isan Chen

Isan Chen, M.D. is board certified in Internal medicine, hematology and medical oncology with more than 20 years of experience in oncology and clinical trials from first-in-humans to global registrational studies. He has experience in oncology clinical development and interactions with regulatory agencies in the US and Europe. He is the Executive VP, Chief Medical & Development Officer of Mirati Therapeutics and was previously the Chief Medical Officer of Aragon Pharmaceuticals which was acquired by Johnson & Johnson in July of 2013. At Aragon, Isan was responsible for the clinical development strategy of all the company’s programs, including prostate (ARN-509) and breast cancer. Prior to Aragon, Isan served as Vice President of tumor strategy in the oncology business unit at Pfizer. In addition, he was the clinical lead for sunitinib, a multiple kinase inhibitor, for the treatment of renal cell carcinoma, an indication in which the drug secured FDA approval in 2006. He was also the clinical lead for the Phase I studies of crizotinib and CDK 4/6 inhibitor palbociclib, both approved for ALK+ NSCLC and breast cancer, respectively. Isan completed his hematology/oncology fellowship at University of California, San Diego. Before joining Pfizer, Isan practiced medical oncology as a staff physician at City of Hope Medical Center and later as an assistant professor at the University of Texas, M.D. Anderson Cancer Center.